Mercado
| Fecha | Título |
|---|---|
| -- |
Five takeaways from the Global Medical Cannabis Market Review 2026The headline shifts across 14 markets — where demand is accelerating, where regulation is the brake, and what it means for market entry. Fuente: Prohibición Partners |
| -- |
Cannabis Telemedicine: What Poland’s Market Crash and Recovery Tells Us About Regulatory RiskCannabis telemedicine has become the dominant access channel in the world’s largest medical cannabis markets, but also their Achilles heel. Fuente: Prohibición Partners |
| -- |
Germany, two years on: what the data actually showsPrescription volumes, pricing and the telemedicine effect — reading the German market beyond the headlines. Fuente: Prohibición Partners |
| -- |
Cannabis Market Research: A Buyer’s Guide to Reports, Data, and Market IntelligenceThe cannabis industry generates more market research than almost any sector of its size. A search for cannabis market data will return dozens of reports, forecasts, and dashboards — many priced at tho... Fuente: Prohibición Partners |
| -- |
Sizing the European opportunity to 2029Where the growth is concentrated across 31 markets, and how to read a forecast you can put in front of an IC. Fuente: Prohibición Partners |
| -- |
What Poland's crash and recovery tells us about regulatory riskA supply shock, a correction, and the lesson for anyone modelling a single-market cannabis thesis. Fuente: Prohibición Partners |
| -- |
The European CBD market: where the value is movingCategory maturity, regulatory drag and the segments still compounding — a read on the numbers. Fuente: Prohibición Partners |
| -- |
UK medical cannabis: the access bottleneck, quantifiedPatient numbers are rising, but access remains the constraint. What the white paper data reveals. Fuente: Prohibición Partners |
| -- |
Consumer Attitudes Toward Psychedelics as Medicine – PSYCH: The Psychedelics As Medicine Report 3rd EditionSurvey findings indicate broad and growing public openness to psychedelics as a medical treatment option: Fuente: Prohibición Partners |
| -- |
Countries to Watch: Where Psychedelic Policy Is Moving Fastest – PSYCH: The Psychedelics As Medicine Report 3rd EditionCanada has a long history of adopting progressive healthcare policies, including early moves on assisted dying and medicinal cannabis. In 2020, Health Canada granted over 20 exemptions allowing access... Fuente: Prohibición Partners |
| -- |
Definitions And Scope- PSYCH: The Psychedelics As Medicine Report 3rd EditionSerotonin is a crucial hormone found in the brain, gut, and throughout the central nervous system (CNS). In the brain, it serves a role as a neurotransmitter, or neuromodulator, and is involved in fun... Fuente: Prohibición Partners |
| -- |
Executive Summary – PSYCH: The Psychedelics As Medicine Report 3rd EditionPsychedelics as medicine are at a crucial inflexion point. A growing number of studies are adding evidence to the astounding effectiveness of psychedelics to treat mental health and substance use diso... Fuente: Prohibición Partners |
| -- |
Glossary – PSYCH: The Psychedelics As Medicine Report 3rd EditionDefinitions of key acronyms and terms used throughout The Psychedelics as Medicine Report . Fuente: Prohibición Partners |
| -- |
Healthcare Providers’ Attitudes Toward Psychedelics as Medicine – PSYCH: The Psychedelics As Medicine Report 3rd EditionFindings from a UK healthcare professional survey suggest a workforce that is engaged with psychedelic research and broadly receptive to psychedelic-assisted therapy (PAT) : Fuente: Prohibición Partners |
| -- |
Key Psychedelic Deep Dives – PSYCH: The Psychedelics As Medicine Report 3rd EditionThe following psychedelic deep dives provide detailed insight into current clinical research, regulatory status, and therapeutic potential across the leading psychedelic compounds being studied global... Fuente: Prohibición Partners |
| -- |
Key Trends – PSYCH: The Psychedelics As Medicine Report 3rd EditionMental health and substance use disorders affect more than 900 million people around the globe according to WHO . Somewhat paradoxically, the more affluent countries are the ones who are dealing with... Fuente: Prohibición Partners |
| -- |
Legislation and Regulation: Global Frameworks and Drug Classification – PSYCH: The Psychedelics As Medicine Report 3rd EditionThe international regulation of psychedelics is primarily governed by the United Nations Convention on Psychotropic Substances , which provides a framework for the global control of substances that af... Fuente: Prohibición Partners |
| -- |
Market Value: The Economics of Psychedelics as Medicine – PSYCH: The Psychedelics As Medicine Report 3rd EditionNote to readers: The value estimates presented here are top-level and provided for informational purposes only. For a more detailed market value forecast, please contact info@psych.global . Fuente: Prohibición Partners |
| -- |
Other Psychedelics of Note – PSYCH: The Psychedelics As Medicine Report 3rd EditionWhile psilocybin, LSD, MDMA, ketamine, ibogaine and ayahuasca currently dominate the development of psychedelics as medicines, a number of other compounds are emerging as credible candidates in their... Fuente: Prohibición Partners |
| -- |
Patents and Intellectual Property in Psychedelic Medicine – PSYCH: The Psychedelics As Medicine Report 3rd EditionPatents cannot be applied to first-generation psychedelic compounds, as the original intellectual property protections expired decades ago. As a result, companies seeking to build defensible intellect... Fuente: Prohibición Partners |
| -- |
Psychedelic Profiles – PSYCH: The Psychedelics As Medicine Report 3rd EditionThe tables below provide a high-level overview of health conditions and psychedelic substances with potential to treat them. Fuente: Prohibición Partners |
| -- |
Psychedelic Research: Clinical Trials, Timelines, and Key Research Groups – PSYCH: The Psychedelics As Medicine Report 3rd EditionPsychedelic research is pushing ahead at a pace never seen before. In the early 2000s, only a handful of researchers were conducting animal studies with mind-altering substances. Today, more than 100... Fuente: Prohibición Partners |
| -- |
Psychedelics and the Law: How Regulation Is Beginning to Change – PSYCH: The Psychedelics As Medicine Report 3rd EditionFor more than 50 years, psychedelic substances have been subject to some of the most restrictive drug control laws in the world. These classifications effectively halted research into their therapeuti... Fuente: Prohibición Partners |
| -- |
Psychedelics as Medicine: Potential Therapies – PSYCH: The Psychedelics As Medicine Report 3rd EditionConventional psychiatric medications, including antidepressants, are associated with a range of negative side effects, and increasing evidence suggests potential adverse effects with long-term use. Fuente: Prohibición Partners |
| -- |
Psychedelics per Country: Research, Companies and Market Activity – PSYCH: The Psychedelics As Medicine Report 3rd EditionThis section provides a country-by-country overview of psychedelic medicine activity, including substances under investigation, the scale of clinical research, notable organisations, and the estimated... Fuente: Prohibición Partners |
| -- |
Psychedelics x Technology – PSYCH: The Psychedelics As Medicine Report 3rd EditionZach Haigney frames the psychedelics–technology intersection as both a practical and a technical issue. Practically, mental healthcare faces a massive unmet need, and psychedelics appear to offer a tr... Fuente: Prohibición Partners |
| -- |
Psychedelics: Timeline of Key Developments – PSYCH: The Psychedelics As Medicine Report 3rd EditionA chronological overview of scientific, regulatory and policy milestones shaping the development of psychedelics as medicines. Fuente: Prohibición Partners |
| -- |
Spotlight on Health: Why Mental Health Needs New Treatment Options – PSYCH: The Psychedelics As Medicine Report 3rd EditionFor decades, psychedelics were discussed mainly in private circles—often associated with alternative healing traditions and non-Western practices. Fuente: Prohibición Partners |
| -- |
Therapy Practitioners in Psychedelic-Assisted Therapy – PSYCH: The Psychedelics As Medicine Report 3rd EditionMore than 50,000 therapists are expected to be trained to administer psychedelic-assisted therapy (PAT) over the next decade. Organisations including MAPS, COMPASS Pathways, the California Institute o... Fuente: Prohibición Partners |